Crossref
US FDA Safety Labeling Change for mRNA COVID-19 Vaccines
JAMA · 16.09.2025 · 334 (11) · 945
DOI: 10.1001/jama.2025.12675 ↗Kurz gefasst
Fachartikel in der Zeitschrift JAMA, erschienen am 16.09.2025. Verfasst von Vinay Prasad und 1 weiteren Autor:innen. Beteiligte Einrichtung: US Food and Drug Administration, Silver Spring, Maryland. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 10 Literaturangaben.
Abstract (Originalsprache)
This Viewpoint explores the US Food and Drug Administration’s institution of a class Safety Labeling Change for messenger RNA (mRNA) COVID-19 vaccines.
Autor:innen und Institutionen
- US Food and Drug Administration, Silver Spring, Maryland.
Zitieren
APA
Prasad, V., & Makary, M. A. (2025). US FDA Safety Labeling Change for mRNA COVID-19 Vaccines. JAMA, 334(11), 945. https://doi.org/10.1001/jama.2025.12675
Vancouver
Prasad V, Makary MA. US FDA Safety Labeling Change for mRNA COVID-19 Vaccines. JAMA. 2025;334(11):945. doi:10.1001/jama.2025.12675
BibTeX
@article{Prasad2025,
author = {Prasad, Vinay and Makary, Martin A},
title = {US FDA Safety Labeling Change for mRNA COVID-19 Vaccines},
journal = {JAMA},
year = {2025},
volume = {334},
number = {11},
pages = {945},
doi = {10.1001/jama.2025.12675}
}
EUVIMED